Developer docs
API playgroundTry for free, no card

Search company profiles

uMotif

Full company profile

uuid0000amm

Namestring
uMotif
Legal namestring
uMotif Limited
Websiteurl
umotif.com
Company typeenum
Private
Founded yearint
2012
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
electronic clinical outcome assessments, patient-reported outcomes platform, electronic consent management, decentralized clinical trials, clinical trial data capture
Industry3 codes
PRIMARYHLACAOAB
eCOA/ePRO/eDiary & Patient-Facing Data Collection
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLACAOAE
eConsent & Digital Identity for Trials
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLACAFAF
Wearables & Consumer IoT Integration Platforms (BYOD)
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
NAICS code2 codes
  • Computer Systems Design and Related Services54151
  • Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services51821
SIC code2 codes
  • Services-Computer Programming, Data Processing, Etc.7370
  • Services-Misc Health & Allied Services, Nec8090
Product category
Clinical Trial eCOA/ePRO Software
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Enterprise eCOA/ePRO Platform Licensing
TypeSubscription Recurring
Description

Primary revenue from licensing the eCOA/ePRO and eConsent platform to pharmaceutical sponsors, biotechs, and CROs on a study-by-study basis. Customer logos page indicates relationships ranging from Top 10 Pharma to emerging biotechs. Pricing is quote-based via 'Book a Demo' rather than publicly disclosed.

umotif.com
2Scientific Consulting Services
TypeProfessional Services
Description

Launched in May 2026 under CSO Florence Mowlem, providing protocol input, eCOA strategy and implementation consulting, study design and build oversight, expert guidance on migration of complex eCOAs, bespoke diary development, and personalized training modules for sites and participants. Includes COA licensing management and translation services.

umotif.com
3Site Solutions / Site Productivity Add-ons
TypeManaged Services
Description

Additional recurring revenue from eConsent (via ClinOne), Trial Awareness (HCP-targeted newsletters and curated specialist network), Patient Engagement (nudges, content, stipends), and Patient Ride (Uber Health integration). Strengthens patient-site relationship as a platform upsell layer.

umotif.com
4CRO Partnership Revenue (Syneos Health)
TypeLicensing Royalties
Description

Through its strategic partnership with Syneos Health, uMotif provides eCOA/ePRO services for Syneos Health customers and co-developed an exclusive patient-centric platform including patient identification, recruitment, eConsent, eDiary, engagement/retention, and payments integrated with StudyKIK.

umotif.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Pricing details1 tier
1Custom quote-based pricing per study
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing is per-study and quote-based, not publicly disclosed; engagement starts via 'Book a Demo' CTA.

umotif.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1MotifAI Assistant
Description

uMotif's AI-driven automation product deployed across the company's clinical trial technology portfolio to deliver faster, higher-quality clinical trials.

prweb.com
Core offering1 text field

uMotif provides a cloud-native, configurable eCOA/ePRO platform that captures electronic Clinical Outcome Assessments (ePRO, eClinRO, eObsRO, ePerfO) across iOS, Android, and web via provisioned, BYOD, and hybrid device models, delivering >90% compliance in clinical and real-world studies. The core platform is augmented by integrated eConsent (via acquired ClinOne), Patient Engagement, Trial Awareness, Patient Ride (Uber Health), and a Care Cluster Solution, plus a separate Scientific Consulting Services practice offering protocol input, eCOA strategy, and COA licensing management. The platform supports 130+ studies, 35+ therapeutic areas, 35 languages, and is GCP, 21 CFR Part 11, and GDPR compliant with cloud hosting in the US, Europe, and China.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • >90% eCOA compliance in clinical trials and real-world studies
+5 more records
Product overview1 text field

uMotif offers a single, modern eCOA/ePRO platform at its core, augmented by a portfolio of integrated modules and services: eConsent, Patient Engagement, Patient Ride (powered by Uber Health), Trial Awareness, the Care Cluster Solution, eDiaries, and Symptom & Drug Tracking. The platform is cloud-native and configured for clinical and real-world studies across all study phases (Phases I–IV) and therapeutic areas, supporting 35+ therapy areas, 130+ studies, and 35 languages. Layered on top of this platform are the new AI-driven MotifAI Assistant capabilities and a separate Scientific Consulting Services offering led by the Chief Scientific Officer that provides protocol input, eCOA strategy, and COA licensing management. The ClinOne site platform (acquired in 2024) extends uMotif's footprint into consent management and site productivity tools. Together these products and modules are designed to strengthen the patient-site relationship and deliver >90% eCOA compliance.

Product and service7 records
1uMotif eCOA/ePRO Platform
CategoryeCOA/ePRO Software Platform
Description

Cloud-native, configurable and scalable eCOA/ePRO platform capturing electronic Clinical Outcome Assessments (ePRO, eClinRO, eObsRO, ePerfO) across provisioned, BYOD, and hybrid device approaches on mobile, tablet, and web for clinical and real-world studies across all phases (I–IV) and 35+ therapeutic areas.

2eConsent
CategoryClinical Trial eConsent Software
Description

Flexible eConsent and consent management solution for informed onboarding, integrated with telehealth to enhance the participant experience and strengthen the patient-site relationship; built on ClinOne's site platform acquired by uMotif in September 2024.

3Patient Engagement
CategoryClinical Trial Patient Engagement Software
Description

Engagement solutions deployed alongside eCOA or as a standalone offering, including nudges and dynamic alerts, content and educational information, patient stipends, and real-time feedback capture to support all phases of research.

4Patient Ride (with Uber Health)
CategoryClinical Trial Site Logistics Software
Description

Non-emergency medical transport for trial participants to and from site visits in the United States, delivered via integration with Uber Health, with centralized billing managed by uMotif within the sponsor's study budget to reduce transportation barriers to enrollment.

5Trial Awareness
CategoryClinical Trial Recruitment and Awareness Software
Description

Trial visibility solution for healthcare providers with potentially eligible patients, using a curated referring specialist network, a bi-weekly newsletter, and study-specific landing pages to drive referrals and enrollment.

6Scientific Consulting Services
CategoryClinical Trial Scientific Consulting Services
Description

Expert scientific consultation across the lifecycle of clinical trials, including protocol input, study design and COA strategy consulting, eCOA modality consultation, eCOA build oversight, migration/implementation guidance, bespoke diary development, and scale management and translations, available to sponsors and CROs globally.

7Care Cluster Solution
CategoryClinical Trial Multi-Caregiver Data Capture Software
Description

Solution enabling data capture from multiple caregivers and participants with clear attribution of exactly who is reporting, particularly valuable in pediatric trials with multiple caregivers, cognitive dysfunction studies, and Parkinson's research where both participant and caregiver perspectives are essential.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
1Xtalks
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2026-06-18
Description

Co-hosted free webinar on June 18, 2026 ('Strengthen Participant-Site Readiness for Complex Rare Disease Trials'), featuring speakers from uMotif, Allucent, Empatica, and Accellacare to discuss reducing participant burden, improving site engagement, and leveraging technology for trial execution.

prnewswire.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-15
Description

Multi-stakeholder collaboration led by uMotif CSO Florence Mowlem PhD on behalf of C-Path, along with co-authors from Top 10 pharma, clinical trial technology providers, and regulators, to produce best-practice recommendations for adopting event-driven eDiaries in clinical trials. The publication was featured in Nature Digital Medicine.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-09-04
Description

uMotif acquired ClinOne, a site platform provider, in September 2024 to integrate ClinOne's consent management and site productivity tools with uMotif's eCOA/ePRO platform. The acquisition consolidates a prior strategic partnership and expands uMotif's offerings to include eConsent. Andrea Valente, previously CEO of ClinOne, subsequently became COO and then CEO of uMotif.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2023-06-01
Description

Strategic partnership in which Syneos Health (Nasdaq:SYNH) combines its StudyKIK recruitment technology and global biopharma services (across 110+ countries) with uMotif's eCOA/ePRO capabilities to deliver an integrated patient-centric eClinical platform covering patient identification, recruitment, eConsent, eDiary, engagement/retention, and payments.

Strategic tierCoreTypeTechnology or Integration
Description

Integration partnership powering uMotif's Patient Ride solution in the United States. Sites use uMotif's online portal to schedule Uber Health rides to/from study visits or approved destinations, with billing centralized and managed by uMotif within the sponsor's study budget to reduce transportation barriers to enrollment.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

uMotif collaborated with IDEO (the global design firm) to develop and hone its patient-first, human-centered software design approach, which is embedded throughout the eCOA/ePRO platform. IDEO's Executive Design Director Betsy Fields Smith is quoted on the Design Approach page.

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Academic research collaboration in which King's College London led the EU Innovative Medicines Initiative-funded Hypo-RESOLVE hypoglycemia study using uMotif's eCOA/ePRO platform (10 weeks, 600 participants across UK and Europe; results published in BMJ Open and Diabetic Medicine).

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research collaboration with uMotif, Parkinson's UK, EPDA, Boston Scientific, Cisco, and UCB Pharma on the 100 for Parkinson's multi-nation decentralized study (4,200+ participants across 60 countries, 2.2M+ data points).

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research collaboration with uMotif and other partners on the 100 for Parkinson's study.

10EPDA (European Parkinson's Disease Association)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research collaboration with uMotif and other partners on the 100 for Parkinson's study.

umotif.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research collaboration with uMotif and other partners on the 100 for Parkinson's study.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research collaboration with uMotif and other partners on the 100 for Parkinson's study.

13UCB Pharma
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research collaboration with uMotif and other partners on the 100 for Parkinson's study.

umotif.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Medidata's Rave eCOA is the dominant enterprise eCOA/ePRO platform, integrated with EDC, IRT, and the broader Medidata Clinical Cloud. Directly comparable to uMotif on ePRO/eCOA functionality, but at vastly greater scale and with deeper incumbent sponsor relationships; competes head-to-head for Top 10 pharma contracts.

TypeDirect peer
Description

Clario (formerly CRF Health/ERT/Bioclinica) is a leading eCOA vendor with deep scientific and endpoint expertise across clinical trials. Directly competes with uMotif for late-phase, multi-modal eCOA programs and is a recognized Leader in the Everest Group eCOA PEAK Matrix against which uMotif is benchmarked.

TypeDirect peer
Description

Signant Health (formerly CRF Health/Bracket) provides eCOA, ePRO, and patient-centric clinical trial solutions for pharma sponsors. Direct peer in ePRO/eCOA with comparable patient-experience focus and similar regulatory positioning; named a Leader in the Everest Group eCOA PEAK Matrix assessment.

TypeBroad incumbent
Description

Veeva Vault eCOA is part of Veeva's broader clinical cloud (Vault CDB, Vault EDC, Vault CTMS). Comparable to uMotif's enterprise eCOA offering but bundled inside a much wider clinical operations platform; competes for global pharma standardization deals.

TypeEmerging player
Description

Medable is a decentralized clinical trial platform with eCOA/ePRO capabilities, founded by former uMotif executives' peers (e.g., incoming uMotif CEO Andrea Valente was previously Medable COO). Direct overlap in decentralized ePRO/eCOA use cases, particularly with consumer-friendly BYOD apps; uMotif's incoming CCO James Thatcher also previously led BD at Medable.

TypeEmerging player
Description

Castor offers an eClinical platform combining EDC, eCOA, ePRO, and eConsent for academic and commercial trials. Comparable to uMotif's integrated platform vision, particularly following the ClinOne acquisition; positioned as a more affordable alternative for emerging biotechs and academic consortia.

TypeEmerging player
Description

YPrime provides eCOA, IRT, and clinical technology solutions with a focus on configurable, modern patient-facing apps. Direct overlap with uMotif's modern eCOA/ePRO platform and similar focus on UX-driven compliance in mid-to-large clinical trials.

TypeEmerging player
Description

ObvioHealth is a decentralized clinical trial platform offering ePRO, eCOA, telemedicine, and remote patient monitoring. Comparable to uMotif in the decentralized and BYOD-enabled ePRO use case; competes for virtual and hybrid trial sponsors.

TypeEmerging player
Description

Evinova is AstraZeneca's digital health unit focused on eCOA, connected devices, and clinical trial solutions. Comparable to uMotif on eCOA/ePRO and adjacent digital health technologies; uMotif's new CCO James Thatcher was previously VP of Business Development at Evinova.

TypeBroad incumbent
Description

IQVIA's Patient Centric Solutions unit provides eCOA/ePRO alongside EDC, IRT, and CRO services at global scale. Broad incumbent that competes with uMotif for enterprise late-phase trials and offers similar multi-modal patient data capture capabilities.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment7 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration8 records

Each record includes

Title, Type, Description, Source

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

uMotif

Clinical Trial eCOA/ePRO Softwareumotif.com

uMotif firmographics

Firmographics
Name
uMotif
Legal name
uMotif Limited
Website
https://umotif.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
101–250 employees
Ownership category
akta.pro rank

uMotif industry classification

Industry
Product category
Clinical Trial eCOA/ePRO Software
NAICS
Computer Systems Design and Related Services (54151), Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services (51821)
SIC
Services-Computer Programming, Data Processing, Etc. (7370), Services-Misc Health & Allied Services, Nec (8090)
akta.pro industry
PRIMARYHLACAOAB
eCOA/ePRO/eDiary & Patient-Facing Data Collection
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLACAOAE
eConsent & Digital Identity for Trials
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLACAFAF
Wearables & Consumer IoT Integration Platforms (BYOD)
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms

Keywords

  • Electronic clinical outcome assessments
  • Patient-reported outcomes platform
  • Electronic consent management
  • Decentralized clinical trials
  • Clinical trial data capture

Where uMotif is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

uMotif business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Enterprise eCOA/ePRO Platform Licensing: Primary revenue from licensing the eCOA/ePRO and eConsent platform to pharmaceutical sponsors, biotechs, and CROs on a study-by-study basis. Customer logos page indicates relationships ranging from Top 10 Pharma to emerging biotechs. Pricing is quote-based via 'Book a Demo' rather than publicly disclosed.
  2. Scientific Consulting Services: Launched in May 2026 under CSO Florence Mowlem, providing protocol input, eCOA strategy and implementation consulting, study design and build oversight, expert guidance on migration of complex eCOAs, bespoke diary development, and personalized training modules for sites and participants. Includes COA licensing management and translation services.
  3. Site Solutions / Site Productivity Add-ons: Additional recurring revenue from eConsent (via ClinOne), Trial Awareness (HCP-targeted newsletters and curated specialist network), Patient Engagement (nudges, content, stipends), and Patient Ride (Uber Health integration). Strengthens patient-site relationship as a platform upsell layer.
  4. CRO Partnership Revenue (Syneos Health): Through its strategic partnership with Syneos Health, uMotif provides eCOA/ePRO services for Syneos Health customers and co-developed an exclusive patient-centric platform including patient identification, recruitment, eConsent, eDiary, engagement/retention, and payments integrated with StudyKIK.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom quote-based pricing per study

Go-to-market motion1 record

Distribution channels3 records

Marketing channels9 records

uMotif product offering

Product offering

Core offering

uMotif provides a cloud-native, configurable eCOA/ePRO platform that captures electronic Clinical Outcome Assessments (ePRO, eClinRO, eObsRO, ePerfO) across iOS, Android, and web via provisioned, BYOD, and hybrid device models, delivering >90% compliance in clinical and real-world studies. The core platform is augmented by integrated eConsent (via acquired ClinOne), Patient Engagement, Trial Awareness, Patient Ride (Uber Health), and a Care Cluster Solution, plus a separate Scientific Consulting Services practice offering protocol input, eCOA strategy, and COA licensing management. The platform supports 130+ studies, 35+ therapeutic areas, 35 languages, and is GCP, 21 CFR Part 11, and GDPR compliant with cloud hosting in the US, Europe, and China.

Product overview

uMotif offers a single, modern eCOA/ePRO platform at its core, augmented by a portfolio of integrated modules and services: eConsent, Patient Engagement, Patient Ride (powered by Uber Health), Trial Awareness, the Care Cluster Solution, eDiaries, and Symptom & Drug Tracking. The platform is cloud-native and configured for clinical and real-world studies across all study phases (Phases I–IV) and therapeutic areas, supporting 35+ therapy areas, 130+ studies, and 35 languages. Layered on top of this platform are the new AI-driven MotifAI Assistant capabilities and a separate Scientific Consulting Services offering led by the Chief Scientific Officer that provides protocol input, eCOA strategy, and COA licensing management. The ClinOne site platform (acquired in 2024) extends uMotif's footprint into consent management and site productivity tools. Together these products and modules are designed to strengthen the patient-site relationship and deliver >90% eCOA compliance.

Differentiator

Problem solved

Functional benefit

Brands

  • MotifAI Assistant: uMotif's AI-driven automation product deployed across the company's clinical trial technology portfolio to deliver faster, higher-quality clinical trials.

Products and services

  • uMotif eCOA/ePRO Platform Cloud-native, configurable and scalable eCOA/ePRO platform capturing electronic Clinical Outcome Assessments (ePRO, eClinRO, eObsRO, ePerfO) across provisioned, BYOD, and hybrid device approaches on mobile, tablet, and web for clinical and real-world studies across all phases (I–IV) and 35+ therapeutic areas.
  • eConsent Flexible eConsent and consent management solution for informed onboarding, integrated with telehealth to enhance the participant experience and strengthen the patient-site relationship; built on ClinOne's site platform acquired by uMotif in September 2024.
  • Patient Engagement Engagement solutions deployed alongside eCOA or as a standalone offering, including nudges and dynamic alerts, content and educational information, patient stipends, and real-time feedback capture to support all phases of research.
  • Patient Ride (with Uber Health) Non-emergency medical transport for trial participants to and from site visits in the United States, delivered via integration with Uber Health, with centralized billing managed by uMotif within the sponsor's study budget to reduce transportation barriers to enrollment.
  • Trial Awareness Trial visibility solution for healthcare providers with potentially eligible patients, using a curated referring specialist network, a bi-weekly newsletter, and study-specific landing pages to drive referrals and enrollment.
  • Scientific Consulting Services Expert scientific consultation across the lifecycle of clinical trials, including protocol input, study design and COA strategy consulting, eCOA modality consultation, eCOA build oversight, migration/implementation guidance, bespoke diary development, and scale management and translations, available to sponsors and CROs globally.
  • Care Cluster Solution Solution enabling data capture from multiple caregivers and participants with clear attribution of exactly who is reporting, particularly valuable in pediatric trials with multiple caregivers, cognitive dysfunction studies, and Parkinson's research where both participant and caregiver perspectives are essential.

Quantifiable outcome

  • >90% eCOA compliance in clinical trials and real-world studies
  • +5 more outcomes

Companies that use uMotif

Customer profile

Named customers9 records

Segments7 records

Ideal customer profiles5 records

uMotif technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration8 records

AI capability1 record

Feature8 records

uMotif partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered minor, core and flagship.

  • XtalksminorGTM or Marketing Partner · 18 June 2026Co-hosted free webinar on June 18, 2026 ('Strengthen Participant-Site Readiness for Complex Rare Disease Trials'), featuring speakers from uMotif, Allucent, Empatica, and Accellacare to discuss reducing participant burden, improving site engagement, and leveraging technology for trial execution.
  • Critical Path Institute (C-Path)coreStrategic or Co-development Partner · 15 December 2025Multi-stakeholder collaboration led by uMotif CSO Florence Mowlem PhD on behalf of C-Path, along with co-authors from Top 10 pharma, clinical trial technology providers, and regulators, to produce best-practice recommendations for adopting event-driven eDiaries in clinical trials. The publication was featured in Nature Digital Medicine.
  • ClinOneflagshipStrategic or Co-development Partner · 4 September 2024uMotif acquired ClinOne, a site platform provider, in September 2024 to integrate ClinOne's consent management and site productivity tools with uMotif's eCOA/ePRO platform. The acquisition consolidates a prior strategic partnership and expands uMotif's offerings to include eConsent. Andrea Valente, previously CEO of ClinOne, subsequently became COO and then CEO of uMotif.
  • Syneos HealthflagshipStrategic or Co-development Partner · 1 June 2023Strategic partnership in which Syneos Health (Nasdaq:SYNH) combines its StudyKIK recruitment technology and global biopharma services (across 110+ countries) with uMotif's eCOA/ePRO capabilities to deliver an integrated patient-centric eClinical platform covering patient identification, recruitment, eConsent, eDiary, engagement/retention, and payments.
  • Uber HealthcoreTechnology or IntegrationIntegration partnership powering uMotif's Patient Ride solution in the United States. Sites use uMotif's online portal to schedule Uber Health rides to/from study visits or approved destinations, with billing centralized and managed by uMotif within the sponsor's study budget to reduce transportation barriers to enrollment.
  • IDEOcoreStrategic or Co-development PartneruMotif collaborated with IDEO (the global design firm) to develop and hone its patient-first, human-centered software design approach, which is embedded throughout the eCOA/ePRO platform. IDEO's Executive Design Director Betsy Fields Smith is quoted on the Design Approach page.
  • King's College LondoncoreImplementation/ SI/ Consulting PartnerAcademic research collaboration in which King's College London led the EU Innovative Medicines Initiative-funded Hypo-RESOLVE hypoglycemia study using uMotif's eCOA/ePRO platform (10 weeks, 600 participants across UK and Europe; results published in BMJ Open and Diabetic Medicine).
  • The Cure Parkinson's TrustcoreStrategic or Co-development PartnerResearch collaboration with uMotif, Parkinson's UK, EPDA, Boston Scientific, Cisco, and UCB Pharma on the 100 for Parkinson's multi-nation decentralized study (4,200+ participants across 60 countries, 2.2M+ data points).
  • Parkinson's UKcoreStrategic or Co-development PartnerResearch collaboration with uMotif and other partners on the 100 for Parkinson's study.
  • EPDA (European Parkinson's Disease Association)coreStrategic or Co-development PartnerResearch collaboration with uMotif and other partners on the 100 for Parkinson's study.
  • Boston ScientificcoreStrategic or Co-development PartnerResearch collaboration with uMotif and other partners on the 100 for Parkinson's study.
  • CiscocoreStrategic or Co-development PartnerResearch collaboration with uMotif and other partners on the 100 for Parkinson's study.
  • UCB PharmacoreStrategic or Co-development PartnerResearch collaboration with uMotif and other partners on the 100 for Parkinson's study.

Scale indicators10 records

Recent moves6 records

Expansion highlights7 records

uMotif competitors and assessment

Company assessment

Broad incumbents

  • Medidata (Dassault Systèmes): Medidata's Rave eCOA is the dominant enterprise eCOA/ePRO platform, integrated with EDC, IRT, and the broader Medidata Clinical Cloud. Directly comparable to uMotif on ePRO/eCOA functionality, but at vastly greater scale and with deeper incumbent sponsor relationships; competes head-to-head for Top 10 pharma contracts.
  • Veeva Systems: Veeva Vault eCOA is part of Veeva's broader clinical cloud (Vault CDB, Vault EDC, Vault CTMS). Comparable to uMotif's enterprise eCOA offering but bundled inside a much wider clinical operations platform; competes for global pharma standardization deals.
  • IQVIA (eCOA / Patient Cented Solutions): IQVIA's Patient Centric Solutions unit provides eCOA/ePRO alongside EDC, IRT, and CRO services at global scale. Broad incumbent that competes with uMotif for enterprise late-phase trials and offers similar multi-modal patient data capture capabilities.

Direct peers

  • Clario: Clario (formerly CRF Health/ERT/Bioclinica) is a leading eCOA vendor with deep scientific and endpoint expertise across clinical trials. Directly competes with uMotif for late-phase, multi-modal eCOA programs and is a recognized Leader in the Everest Group eCOA PEAK Matrix against which uMotif is benchmarked.
  • Signant Health: Signant Health (formerly CRF Health/Bracket) provides eCOA, ePRO, and patient-centric clinical trial solutions for pharma sponsors. Direct peer in ePRO/eCOA with comparable patient-experience focus and similar regulatory positioning; named a Leader in the Everest Group eCOA PEAK Matrix assessment.

Emerging players

  • Medable: Medable is a decentralized clinical trial platform with eCOA/ePRO capabilities, founded by former uMotif executives' peers (e.g., incoming uMotif CEO Andrea Valente was previously Medable COO). Direct overlap in decentralized ePRO/eCOA use cases, particularly with consumer-friendly BYOD apps; uMotif's incoming CCO James Thatcher also previously led BD at Medable.
  • Castor: Castor offers an eClinical platform combining EDC, eCOA, ePRO, and eConsent for academic and commercial trials. Comparable to uMotif's integrated platform vision, particularly following the ClinOne acquisition; positioned as a more affordable alternative for emerging biotechs and academic consortia.
  • YPrime: YPrime provides eCOA, IRT, and clinical technology solutions with a focus on configurable, modern patient-facing apps. Direct overlap with uMotif's modern eCOA/ePRO platform and similar focus on UX-driven compliance in mid-to-large clinical trials.
  • ObvioHealth: ObvioHealth is a decentralized clinical trial platform offering ePRO, eCOA, telemedicine, and remote patient monitoring. Comparable to uMotif in the decentralized and BYOD-enabled ePRO use case; competes for virtual and hybrid trial sponsors.
  • Evinova (AstraZeneca): Evinova is AstraZeneca's digital health unit focused on eCOA, connected devices, and clinical trial solutions. Comparable to uMotif on eCOA/ePRO and adjacent digital health technologies; uMotif's new CCO James Thatcher was previously VP of Business Development at Evinova.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

uMotif social profiles

Digital presence

uMotif compliance and trust

Trust signal

Compliance2 records

uMotif financial estimates

Financial estimate

Revenue estimate

Valuation estimate

uMotif leadership team

Management profile

Number of profiles

Profiles13 records

uMotif subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

uMotif funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

uMotif M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about uMotif

What does uMotif do?

uMotif provides a cloud-native, configurable eCOA/ePRO platform that captures electronic Clinical Outcome Assessments (ePRO, eClinRO, eObsRO, ePerfO) across iOS, Android, and web via provisioned, BYOD, and hybrid device models, delivering >90% compliance in clinical and real-world studies. The core platform is augmented by integrated eConsent (via acquired ClinOne), Patient Engagement, Trial Awareness, Patient Ride (Uber Health), and a Care Cluster Solution, plus a separate Scientific Consulting Services practice offering protocol input, eCOA strategy, and COA licensing management. The platform supports 130+ studies, 35+ therapeutic areas, 35 languages, and is GCP, 21 CFR Part 11, and GDPR compliant with cloud hosting in the US, Europe, and China.

Is uMotif a public or private company?

uMotif is a private company. It is classified as venture growth investor backed and is currently operating.

When was uMotif founded?

uMotif was founded in 2012. It employs 101 to 250 people.

Where is uMotif based?

uMotif is headquartered in London, United Kingdom, in the Europe region.

How does uMotif make money?

Four revenue lines are on record. Enterprise eCOA/ePRO Platform Licensing is the primary driver. The others are scientific Consulting Services, site Solutions / Site Productivity Add-ons and CRO Partnership Revenue (Syneos Health).

Who are uMotif's main competitors?

Broad incumbents on record are Medidata (Dassault Systèmes), Veeva Systems and IQVIA (eCOA / Patient Cented Solutions). Direct peers are Clario and Signant Health. Emerging players are Medable, Castor, YPrime, ObvioHealth and Evinova (AstraZeneca).

Does uMotif have an API?

No public API is recorded for uMotif.

What industry is uMotif in?

uMotif's product category is Clinical Trial eCOA/ePRO Software. Its primary akta.pro industry code is HLACAOAB, eCOA/ePRO/eDiary & Patient-Facing Data Collection, with a secondary code of HLACAOAE, eConsent & Digital Identity for Trials. Its NAICS code is 54151 and its SIC code is 7370.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PrwebuMotif to Showcase Modern eConsent and eCOA Platform to Bolster the Pivotal Patient-Site Relationship in Clinical Trials at Life Sciences EventsuMotif will showcase its eConsent and eCOA platform at 12 conferences and symposia, including therapeutic-specific forums for epilepsy, oncology, and obesity. The company recently appointed Andrea Valente as CEO, James Thatcher as Chief Commercial Officer, and launched Scientific Consulting Services under Florence Mowlem PhD.PrwebuMotif Chief Scientific Officer Florence Mowlem PhD Wins PCMG Outsourcing Trailblazer of the Year AwarduMotif Chief Scientific Officer Florence Mowlem PhD was named Outsourcing Trailblazer of the Year at the PCMG Awards 2026 ceremony held in Berlin on June 16. The award recognizes her scientific leadership in electronic clinical outcome assessment and digital health technologies for endpoint data collection in clinical trials. PCMG cited her visible thought leadership in the rapidly growing eCOA technology sector and her ongoing work helping sponsors modernize their digital outcomes strategies.PrwebuMotif Announces Andrea Valente is Chief Executive OfficerAndrea Valente has been named CEO of uMotif, effective June 1, 2026, succeeding Steve Rosenberg, who will remain on the board. Valente previously served as COO and was CEO of ClinOne, which uMotif acquired in September 2024. Her appointment follows recent hires and the launch of Scientific Consulting Services.PR NewswireStrengthen Participant-Site Readiness for Complex Rare Disease Trials, Upcoming Webinar Hosted by XtalksXtalks has announced a free webinar on June 18, 2026, focused on strengthening participant-site readiness for complex clinical trials, particularly in rare diseases. The webinar will feature speakers from uMotif, Allucent, Empatica, and Accellacare discussing topics including reducing participant burden, improving site engagement, and leveraging technology to streamline trial execution.PrwebeCOA Platform Innovator uMotif Launches Scientific Consulting ServicesuMotif, a clinical trial technology company specializing in electronic Clinical Outcome Assessment (eCOA) platforms, has launched new Scientific Consulting Services led by Chief Scientific Officer Florence Mowlem PhD. The new offering provides sponsors and CROs with scientific oversight across clinical trial design areas including protocol input, eCOA strategy and implementation, and COA licensing management. The company states that successful eCOA studies require unrivalled technology, strong scientific underpinning, and excellent operational execution.PrwebuMotif Appoints James Thatcher Chief Commercial OfficeruMotif Ltd announced the appointment of James Thatcher as Chief Commercial Officer on May 5, 2026, effective immediately. Thatcher brings extensive experience from Evinova, where he served as Vice President of Business Development, and previously from Medable, where he was Executive Director of Business Development. He will be responsible for driving commercial strategy, sales leadership, and new business development initiatives across uMotif's global client base.PrwebuMotif CEO Steve Rosenberg, Visionary Clinical Trial Technology Leader, to Retire; Industry Veteran and uMotif COO Andrea Valente to Take on Top RoleSteve Rosenberg will retire as CEO of uMotif, effective June 1, 2026, with COO Andrea Valente named as his successor. Under Rosenberg's leadership, uMotif has grown into a provider of patient-first eConsent and eCOA technologies for complex clinical trials and real-world studies. Rosenberg will remain on the company's Board of Directors following the transition.PrwebuMotif Chief Scientific Officer Leads Publication of Fundamental Work Detailing Industry-Wide Recommendations for Adopting Event-Driven eDiaries in Clinical TrialsuMotif Chief Scientific Officer Florence Mowlem led a project on behalf of the Critical Path Institute to develop 10 best practices for event-driven eDiaries (EDeDs) in clinical trials, with the recommendations now published in Nature Digital Medicine. The initiative involved 23 co-authors from leading pharmaceutical companies, clinical trial technology providers, regulators, and research organizations. This collaborative effort represents an industry-wide push to improve how patient data is captured in clinical trials.outsourcing-pharma.comuMotif expands site and patient platform with ClinOne acquisitionuMotif acquired ClinOne on September 4, 2024, integrating its consent management, site productivity, and trial awareness tools into its eCOA/ePRO platform. The move strengthens patient and site experience, building on a two-year partnership. uMotif also appointed Florence Mowlem as Chief Scientific Officer.ClinicalresearchnewsonlineuMotif Buys ClinOneuMotif has acquired ClinOne, finalizing a two-year strategic partnership aimed at integrating electronic clinical outcomes assessment (eCOA) and electronic informed consent technologies. Financial terms of the acquisition were not disclosed, but the entire ClinOne team will join uMotif, with CEO Andrea Valente taking on a senior leadership role. This move combines uMotif's patient-focused data platforms with ClinOne's site productivity tools to create a more comprehensive solution for clinical trials.